Cambridge-based LoQus23 Therapeutics has closed a £35 million Series A financing.

Edinburgh-based Resolution Therapeutics appointed Paul Sekhri as chair, replacing Lisa Bright.

Resolution Therapeutics has raised £63.5 million in Series B financing, led by Syncona.

Constructive Bio has secured $58 million in the first close of its Series A round led by Ahren, OMX Ventures and Paladin Capital Group.

Broken String Biosciences, has appointed Laurence Reid as chairman, and Brad Crutchfield as a non-executive director.

London based biopharma company Vicebio has raised $100 million in Series B round led by TGCX, to accelerate development of respiratory vaccines.

Celadon Pharmaceuticals which focuses on the development, production and sale of cannabis-based medicines, has raised £1.05 million through the issue of shares.

Cambridge-based techbio drug development company Closed Loop Medicine has appointed Luba Greenwood as its chair.

Sphere Fluidics, a provider of microfluidics-based solutions for single-cell analysis and isolation, has appointed Dr Alex Dickinson as a non-executive director.

Cambridge-based PhoreMost, a biopharmaceutical company unlocking drug targets, has added $12 million to its Series B financing.

Growth strategy consulting firm CIL has hired Frédéric Thomas as a partner to lead its French operations and be part of its global healthcare and life sciences practice.

Alderley, Chesire headquartered Gentronix, genetic toxicology services firm has been acquired by Scantox Group, a Danish toxicology services firm for an undisclosed sum.

Biotechnology company SpyBiotech has appointed Dr Prakash Bhuyan as chief medical officer.

Molecular sensing technology developer Oxford Nanopore has secured a £50 million investment from Novo Holdings.

Cambridge-based AI-enabled drug discovery startup Healx, has raised $47 million in a Series C round, co-led by Atomico and R42.

London-based Bioniq will use the proceeds to expand its global market share in personalised supplements.

Optibrium, a drug discovery software provider to the pharmaceutical and biotech industries, has appointed James Halle as chief commercial officer.

Cellular Origins, a TTP company focused on enabling manufacture of cell and gene therapies, has appointed Geoffrey Hodge as a non-executive director.

Clinical stage biotech firm Asceneuron has raised $100m in latest round, led by Novo Holdings.

British-Swedish multinational pharmaceutical company AstraZeneca has completed acquisiton of Lyon-based Amolyt Pharma for up to $1.05 billion.

Newcastle upon Tyne-based Newcells Biotech has appointed Emile Shaffu as director of sales.

MedPharm, a Guildford-based CDMO and Tergus Pharma, North Carolina based pharmaceuticals company have announced a merger under the name of MedPharm.

Biotech company Myricx Bio has closed a Series A financing raising £90 million.

London-based pharmaceutical company CNX Therapeutics has appointed Claire Masterson as chief financial officer, replacing Olga Lund.

London-based cancer therapy developer Granza Bio, has secured $7 million in a seed round led by Felicis Venture Capital, Refactor Capital and Y Combinator.

Pharma and biopharma marketing agency remarketing has appointed Elliott Gibson as head of data and insights and promoted Matt Dent to head of delivery.

Cambridge-based CN Bio has appointed Lydia Seymour as vice-president of people and culture.

London-based life science investor Syncona has added two companies to its portfolio, iOnctura and Yellowstone Biosciences.

EpilepsyGTx, a biotechnology company focused on gene therapies to treat focal refractory epilepsy, has raised $10 million in seed funding.

Enterprise Therapeutics has appointed Dr Renu Gupta as chief medical officer and Dr Janet Hammond as a non-executive director.

SpyBiotech, a biotechnology company, has appointed Keith Dewedoff as chief financial officer.

US pharmaceutical firm Merck has acquired Eyebiotech Limited (EyeBio), a London-based ophthalmology focused biotech company.

Closed Loop Medicine has appointed Paul Johnson as an independent non-executive director.

Laboratory services group Biofortuna has acquired sample storage specialist Cryoniss.

Cambridge Cognition has appointed Charlie Mains as vice-president of business development.

Kester Capital's portfolio company, MAP Patient Access, has acquired AxTalisa, a provider of market access, medical affairs and regulatory consulting services.

Enhanc3D Genomics, which develops disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, has appointed Hazel Jones as chief executive.

Cambridge-based techbio company Qureight has appointed Dr Simon Walsh as chief scientific officer.

Vector Consumer Group, a collagen supplement producer, is seeking acquisition targets to bolster its presence in Asia.

TMC Pharma Services, a global product development and clinical research organisation has appointed Simon Estcourt as chief executive.

Cambridge Cognition has reported an adjusted 2023 operating loss of £1.1 million.

Monument Therapeutics, a precision neuroscience company spun-out from Cambridge Cognition, has completed a fundraise and has received grant funding.

CN Bio has raised $21 million in Series B funding.

EnteroBiotix, a clinical-stage biotechnology company developing full-spectrum microbiome therapeutics, has completed a £27 million funding round.

British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca is acquiring Lyon-based Amolyt Pharma for up to $1.05 billion in total consideration.

Paris-based biopharma private equity fund Jeito Capital has appointed Sarah Leroy to the newly created position of secretary general.

Nuclera, a biotechnology company enabling rapid protein expression and purification screening through its benchtop protein platform, has appointed Joseph Bertelsen as chief commercial officer.

Aspire Pharma, a specialty generics business, has acquired Cenoté Pharma, a specialist in carnitine deficiencies.

Biotechnology company MIP Discovery has closed a £7 million Series A financing round, led by Mercia Ventures.

Maxion Therapeutics, a biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, has appointed Dr Arndt Schottelius as chief executive.

CN Bio, an organ-on-a-chip company that designs and manufactures single-and multi-organ microphysiological systems, has appointed Joseph Parisi as US director of sales.

Enhanc3D Genomics, which develops disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, has appointed Dr Daniel Turner as chief scientific officer.

Enterprise Therapeutics has closed a £26 million Series B follow-on financing round, led by Panakes Partners.

Sano Genetics, a software company in the precision medicine research field, has raised $11.4 million in funding, led by Plural.

Cumulus Oncology has raised £9 million in seed ¬financing in a round led by existing investor Eos Advisory and new corporate investor, the Scottish National Investment Bank.

Arecor Therapeutics has appointed Dr Helen Parris as senior vice-president, commercial, as well as general manager of the group’s subsidiary company, Tetris Pharma.

London-based Celadon Pharmaceuticals, which focuses on the development, production and sale of cannabis-based medicines, is raising £2 million through a share issue.

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has appointed Dr Nicola Thompson as its chair

Cyted, which works on non-endoscopic diagnostics for digestive diseases, has appointed Gail Marcus as its chair and a non-executive director.

Cancer Research Horizons has appointed Jonathan Tobin and Genghis Lloyd-Harris as advisory investors-in-residence in its ventures team.

The transaction comes on the heels of the immuno-oncology contract research business, Antibody Analytics, which was acquired in early November.

NanoSyrinx has appointed Dr Anthony Johnson as a non-executive director.

Kelso Pharma, a UK-based specialty pharma business, has acquired an Italian specialty pharma company as part of its European expansion plans.

Enhanc3D Genomics has appointed Hazel Jones as chief operating officer.

Recruitment company The IN Group has acquired BioTalent, a life sciences recruitment specialist.

NorthEdge has completed a multimillion-pound investment into Antibody Analytics, a contract research organisation.

M&G Investments has invested in SkyCell, which supplies containers and technological solutions for delivery of pharmaceuticals.

Kelso Pharma has acquired two UK approved products from an organisation within the Dermapharm Group.

Biotech company Mestag Therapeutics has appointed Dr Cassandra Choe-Juliak, Dr Greg Elson and Samantha Vieira as expert advisors.

AstronauTx has completed a £48 million Series A financing led by the Novartis Venture Fund.

Closed Loop Medicine has appointed Konstantinos Vlassis as chief technology officer.

Forward Partners-backed Sonrai Analytics, an AI precision medicine company, has appointed Paul Jones as chairman.

Cambridge-based techbio company Qureight has appointed Dr Claus Torp Jensen as its chairperson.

Biotechnology company CellCentric, has secured a further $3 million investment from BrightEdge.

Private equity firm Permira has agreed to buy Guildford-based biopharmaceutical company Ergomed for about £703.1 million.

Optibrium has acquired BioPharmics, a developer of algorithms and software for 3D ligand and structure-based computational drug design.

Glasgow-based digital pharmacy company Phlo Technologies has appointed Alistair Murray as chief pharmacist. 

Destiny Pharma has appointed Sir Nigel Rudd as chairman.

Destiny Pharma has appointed Chris Tovey as chief executive.

A global clinical trials company is making preparations for its highly-anticipated second round of bidding.

London-based Tenpoint Therapeutics has raised $70 million Series A financing to continue developing eye therapeutics.

Camena Bioscience has closed a $10 million Series A financing round, led by Mercia.

EDX Medical Group has appointed Dr Keti Zeka as head of R&D and director of laboratories and Dr Liam Dower as head of quality, regulatory affairs and compliance.

Avacta Group, a life sciences company developing oncology drugs and diagnostics, has appointed Shaun Chilton as a non-executive director.

TMC Pharma Services has appointed Stewart Sharpe as chief commercial officer.

Pneumagen, a clinical stage biotech company, has secured £8 million in financing.

Chancellor of the Exchequer Jeremy Hunt has revealed a £650 million war chest to bolster economic growth in the UK's Life Sciences sector.

EQT Life Sciences has closed its inaugural LSP Dementia Fund, raising approximately €260 million.

Neuro-Bio, an Abingdon-based biotech company with a therapeutic focus on Alzheimer’s Disease, will close a £10m Series C round by Q3 2023.

Kester Capital, a UK lower mid-market private equity specialist, has invested in MAP Patient Access, a consulting services provider to the pharmaceutical and biotech sectors, Private Equity Wire has reported.

Mansfield Advisors has appointed Dr Misha Engineer and Dr Ed Kanalosh as senior advisors.